1. Home
  2. SCYX vs BGI Comparison

SCYX vs BGI Comparison

Compare SCYX & BGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SCYNEXIS Inc.

SCYX

SCYNEXIS Inc.

HOLD

Current Price

$0.66

Market Cap

24.6M

Sector

Health Care

ML Signal

HOLD

Logo Birks Group Inc.

BGI

Birks Group Inc.

N/A

Current Price

$1.08

Market Cap

22.7M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
SCYX
BGI
Founded
1999
1879
Country
United States
Canada
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
24.6M
22.7M
IPO Year
2014
2005

Fundamental Metrics

Financial Performance
Metric
SCYX
BGI
Price
$0.66
$1.08
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$3.00
N/A
AVG Volume (30 Days)
563.4K
23.9K
Earning Date
11-05-2025
12-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,932,000.00
$136,846,182.00
Revenue This Year
$167.73
N/A
Revenue Next Year
$290.78
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
7.45
52 Week Low
$0.57
$0.56
52 Week High
$1.49
$2.03

Technical Indicators

Market Signals
Indicator
SCYX
BGI
Relative Strength Index (RSI) 45.86 45.07
Support Level $0.65 $1.00
Resistance Level $0.72 $1.11
Average True Range (ATR) 0.05 0.04
MACD 0.01 -0.00
Stochastic Oscillator 54.91 57.17

Price Performance

Historical Comparison
SCYX
BGI

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

About BGI Birks Group Inc.

Birks Group Inc is a part of the leisure industry. The company designs, develops, produces, and retails fine jewelry, timepieces, and gifts. Its operating segments include Retail and Other. The company generates maximum revenue from the Retail segment. Its retail segment consists of retail operations whereby it operates stores in Canada under the Maison Birks, Brinkhaus, Graff, and Patek Phillippe brands. The other segment consists mainly of wholesale business, e-commerce business, and gold exchange business.

Share on Social Networks: